UNSPSC 51431802: Diclofurime

This classification denotes a calcium channel blocker with the molecular formula C18H22Cl2N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D1FP3K444H, chemically known as 2,3-dichloro-4-methoxyphenyl 2-furyl ketone (e)-o-(2-(diethylamino)ethyl)-oxime. but generally known as diclofurime, which bears US NIH Compound Identifier 9577638. European Medicines Agency schedules Diclofurime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07095MIG.

UNSPSC 51431802 Diclofurime, a Commodity code, encompasses emergency medications and pharmaceutical supplies procured by state and local government agencies for fire, rescue, and health services operations. Recent solicitations show state and local buyers acquiring specific medications for emergency medical protocols — principally emergency life support drugs such as epinephrine, adenosine, diltiazem, and labetalol supplied to fire rescue departments and hospital networks. The issuing bodies span city purchasing departments (notably the City of Tampa), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). These buyers source both individual medication line items in modest volumes and participate in larger coordinated procurement frameworks for generic pharmaceuticals and OTC products distributed across health systems and emergency response networks.

Recent activity centers in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications for Tampa Fire Rescue, requesting sealed bids for four specific medication line items totaling approximately 3,530 units with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00; the solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct contracting relationships between the state pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (administered by the Minnesota Department of Administration's Office of State Procurement) issued an RFP (S1070000015802) with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for participating state and local government facilities, requiring manufacturers to supply through three authorized wholesalers and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.